Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and Heart Test Laboratories (NASDAQ:HSCS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Anteris Technologies Global and Heart Test Laboratories, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 0 | 0 | 4 | 0 | 3.00 |
| Heart Test Laboratories | 0 | 0 | 2 | 0 | 3.00 |
Anteris Technologies Global currently has a consensus target price of $16.50, indicating a potential upside of 130.13%. Heart Test Laboratories has a consensus target price of $13.50, indicating a potential upside of 301.79%. Given Heart Test Laboratories’ higher possible upside, analysts clearly believe Heart Test Laboratories is more favorable than Anteris Technologies Global.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | N/A | N/A | N/A | N/A | N/A |
| Heart Test Laboratories | $14,700.00 | 224.00 | -$6.61 million | ($7.91) | -0.42 |
Anteris Technologies Global has higher earnings, but lower revenue than Heart Test Laboratories.
Institutional and Insider Ownership
17.2% of Heart Test Laboratories shares are held by institutional investors. 1.8% of Heart Test Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Anteris Technologies Global and Heart Test Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | N/A | N/A | N/A |
| Heart Test Laboratories | N/A | -117.76% | -84.09% |
Summary
Heart Test Laboratories beats Anteris Technologies Global on 4 of the 7 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
About Heart Test Laboratories
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
